| Wednesday July 3, 2013 |
| 10:00 | Registration |
|
| 11:30 | Reaxys Workshop: Making Drug Development Easier – Reaxys Medicinal Chemistry |
|
| 14:00 | Introductive remarks |
Dr Maria DUCA (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Dr Stéphane AZOULAY (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Prof. Frédérique VIDAL (UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Nice, France)
Prof. Hans Ulrich STILZ (NOVO NORDISK, Malov, Denmark)
Dr Pascal GEORGE (SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France) |
| Session 1: Paul Ehrlich Prize Lecture - Sponsored by Janssen-Cilag |
|
| Session Chairmen |
Prof. André TARTAR (UNIVERSITY LILLE 2, Lille, France)
Dr Sandrine VENDEVILLE (JANSSEN INFECTIOUS DISEASES, Beerse, Belgium) |
| 14:15 | Of Ionic Channels, Venom Toxins and Other Natural Substances ... and Diseases |
Prof. Michel LAZDUNSKI
(INSTITUT DE PHARMACOLOGIE MOLECULAIRE ET CELLULAIRE (IPMC), Nice, France) |
| Session 2: Ion Channels |
|
| Session Chairman |
Prof. Claudiu SUPURAN
(UNIVERSITY OF FIRENZE, Sesto Fiorentino, Italy) |
| 15:15 | Ion Channel Drug Discovery: a Medicinal Chemistry Perspective |
Dr Robert OWEN
(PFIZER NEUSENTIS, Cambridge, United Kingdom) |
| 16:00 | Discovery of Potent and Selective Inhibitors of the Cardiac Sodium/Calcium Exchanger (NCX-1) |
Dr Hartmut SCHIROK
(BAYER, Wuppertal, Germany) |
| 16:45 | Coffee Break and Exhibition |
|
| Session 3: Synergies between Medicinal Chemistry and Biotechnology
Sponsored by Pierre Fabre Research Institute |
|
| Session Chairman |
Dr Pascal GEORGE
(SCT & INDEPENDENT SCIENTIFIC EXPERT & ADVISER, Longvilliers, France) |
| 17:45 | Strategies and Challenges for the Next Generation of Therapeutic Antibodies and Derivatives |
Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France) |
| 18:30 | Welcome Reception |
|
| Thursday July 4, 2013 |
Session 4:
Case Studies, Immunology & Inflammation | Session 5:
Fragment-Based Drug Design |
| Session Chairman |
Dr Gordon TANG
(ROCHE, Shanghai, China) |
| 08:45 | GLPG0974, a FFA2 Antagonist from Hit to Clinic |
Dr Laurent SANIERE
(GALAPAGOS, Romainville, France) |
| 09:30 | Discovery of Highly Potent, Selective and Efficacious Cathepsin S Inhibitors |
Dr Wolfgang HAAP
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
|
| Session Chairman |
Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France) |
| 08:45 | Fragment Screening and Drug Design with Fluorine NMR Spectroscopy |
Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland) |
| 09:30 | All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery |
Dr James MURRAY
(VERNALIS, Cambridge, United Kingdom) |
|
|
| 10:15 | Coffee Break, Poster Session and Exhibition |
|
| Session 6: Druggability | Session 7: ChemoGenomic |
| Session Chairman |
Dr Luc VAN HIJFTE
(SCT & NOVALIX, Illkirch, France) |
| 10:45 | Improving Compound Quality in Medicinal Chemistry |
Dr Paul LEESON
(ASTRAZENECA, United Kingdom) |
| 11:30 | ADMET Modelling: Where is it Worth the Effort? |
Dr Richard LAW
(EVOTEC, Abingdon, United Kingdom) |
|
| Session Chairman |
Dr Paola ARIMONDO
(CNRS - PIERRE FABRE, Toulouse, France) |
| 10:45 | High Confidence Target and Pathway Prediction Using a Robust Chemogenomic Platform |
Dr Stephen HELLIWELL
(NOVARTIS, Basel, Switzerland) |
| 11:30 | The Discovery of Small Molecule Inhibitors of Jumonji Enzymes: Probing the Epigenome |
Dr Jack BROWN
(EPINOVA DPU, II TAU, GLAXOSMITHKLINE, Stevenage, United Kingdom) |
|
|
| 12:15 | Lunch, Poster Session and Exhibition |
|
| 14:00 | Career Session |
|
| Session 8: Molecular Networks |
| Session Chairman |
Prof. Hans Ulrich STILZ
(NOVO NORDISK, Malov, Denmark) |
| 14:15 | Molecular Networks : Drug Action and Genome-Informed Medicine |
Prof. Giulio SUPERTI-FURGA
(RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria) |
|
|
| Session 9: Case Studies, Anti-Infective Agents 1 | Session 10: ChemBioTools |
| Session Chairman |
Dr Yves P. AUBERSON
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 15:00 | Natural Products as Leads for Drug Discovery |
Prof. Karl-Heinz ALTMANN
(ETH ZURICH, Zurich, Switzerland) |
| 15:45 | Drugs for Bad Bugs - Strategies to Address Infections by Multidrug-resistant Bacteria |
Dr Jean-Philippe SURIVET
(ACTELION, Allschwil, Switzerland) |
|
| Session Chairman |
Dr Aline MOULIN
(FLAMEL TECHNOLOGIES, Vénissieux, France) |
| 15:00 | Developing New Tools for Cancer Diagnostics and Therapeutics: Fluorescent Peptide Biosensors of Cyclin-Dependent Kinases |
Dr May MORRIS
(CENTRE DE RECHERCHE EN BIOCHIMIE MACROMOLÉCULAIRE (CRBM) - CNRS, Montpellier, France) |
| 15:45 | Beyond Antithrombotics: Synthetic Approaches to Unravel New Therapeutic Potentials for Glycosaminoglycans |
Prof. David BONNAFFÉ
(UNIVERSITY PARIS-SUD, Orsay, France) |
|
|
| 16:30 | Coffee Break, Poster Session and Exhibition |
|
Session 11: Case Studies: Anti-Infective Agents 2
Sponsored by GlaxoSmithKline | Session 12: GPCR |
| Session Chairman |
Dr Alexis DENIS
(GSK, Courtaboeuf, France) |
| 17:00 | Validation of Protein Kinases as Drug Targets in the African Trypanosome |
Prof. Jeremy MOTTRAM
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom) |
| 17:45 | Drug Discovery for Diseases of the Developing World |
Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom) |
|
| Session Chairman |
Dr Stephan SCHANN
(DOMAIN THERAPEUTICS, Strasbourg, France) |
| 17:00 | Structure and Fragment Based Drug Design for G Protein-Coupled Receptors |
Dr Miles CONGREVE
(HEPTARES, Welwyn Garden City, United Kingdom) |
| 17:45 | Allosteric Modulation of the Chemokine Receptor CXCR3 |
Dr Nuska TSCHAMMER
(UNIVERSITY OF ERLANGEN-NÜRNBERG, Erlangen, Germany) |
|
|
| 20:00 | Symposium Banquet |
|
| Friday July 5, 2013 |
| Session 13: Breaking News |
|
| Session Chairman |
Dr Frédéric DOLLE
(CEA, SERVICE HOSPITALIER FRÉDÉRIC JOLIOT, Orsay, France) |
| 08:30 | Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety |
Dr Claire BOUIX-PETER
(GALDERMA R&D, Sophia-Antipolis, France) |
| 09:15 | SOM230: A New Therapeutic Modality for Cushing’s Disease |
Dr Ian LEWIS
(NOVARTIS, Basel, Switzerland) |
| 10:00 | Coffee Break, Poster Session and Exhibition |
|
| Session 14: Antibody Drug Conjugates
Sponsored by Pierre Fabre Research Institute |
|
| Session Chairman |
Dr Alain BECK
(PIERRE FABRE, St Julien-en-Genevois, France) |
| 10:30 | Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy |
Dr Ravi CHARI
(IMMUNOGEN, Waltham, United States) |
| 11:15 | Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics |
Dr Jagath Reddy JUNUTULA
(GENENTECH, South San Francisco, United States) |
| Session 15: European Lead Factory
Sponsored by ELF Chemistry SMEs : Edelris, Mercachem, Sygnature, Syncom, Taros |
|
| Session Chairman |
Prof. Joachim MITTENDORF
(BAYER PHARMA AG, Wuppertal, Germany) |
| 12:00 | The European Lead Factory - A Novel Discovery Partnership Model |
Dr Jörg HUESER
(BAYER PHARMA, Wupperthal, Germany) |
| 12:35 | Lunch, Poster Session and Exhibition |
|
| Session 16: Case Studies, Pain & Cancer |
|
| Session Chairman |
Dr Henning STEINHAGEN
(GRÜNENTHAL, Verona, Italy) |
| 14:05 | DAAO Inhibitors as Clinical Candidates |
Dr Michele HEFFERNAN
(SUNOVION PHARMACEUTICALS, Marlborough, United States) |
| 14:50 | How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway |
Dr Eric LINGUEGLIA
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France) |
| 15:25 | Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers |
Dr Frank HALLEY
(SANOFI, Vitry-sur-Seine, France) |
| 16:10 | Poster Prizes and Conclusive Remarks |
Prof. Janos SAPI
(SCT & UNIVERSITY OF REIMS-CHAMPAGNE-ARDENNE, Reims, France) |
| |
|
